Tag Archives: generics

Momenta CEO Rebuffs Teva's Copaxone Defense

Momenta Pharmaceuticals’ CEO Craig Wheeler said comments made by Teva leadership about a “purported” generic of Copaxone are “kind of humorous.” Teva’s Copaxone, a multiple sclerosis drug that earns nearly $4 billion a year, is approaching patent expiry – and possible generic competition – on May 24. Assuming FDA approves a generic version of Copaxone, […]
Posted in Biotech, FDA, IP, leadership, Legal, People, pricing, R&D, Regulatory, Strategy | Also tagged , , , , , , | Leave a comment

Liability Looms for Generic Drug Safety Labeling Changes

FDA is proposing to revise its rules to permit generic drug manufacturers to initiate safety labeling changes, and not wait until the brand company takes that action. The aim of the new policy is to inform consumers more quickly of emerging safety concerns – but it also could create confusion by allowing prescribing information to […]
Posted in FDA, Legal, Regulatory, Safety | Also tagged , , , , , , | 1 Comment

Rx Brand Managers: Will Your Products Be Covered Under Obamacare?

by Tom Norton We are now less than three weeks away from the initial sign up period for Obamacare. After October 1st, the reality of the program and all that it portends for the future of the US pharmaceutical industry will begin to make itself apparent. One area that is of extreme concern to Rx […]
Posted in Guest Blog, healthcare, Legal, Market Access, Regulatory, Strategy | Also tagged , , , , , , , | Leave a comment

Mutual v. Bartlett: A Line in the Sand on Side Effects

The Supreme Court ruled last Monday in the case of Mutual Pharmaceuticals v. Bartlett that generic drug makers cannot change labeling or the formula of a drug after it has been approved by the FDA. The majority, which included Justices Alito, Roberts, Scalia, Kennedy, and Thomas, concluded that federal regulation trumps state tort liability law, […]
Posted in FDA, Legal, Market Access, Marketing, Regulatory, Safety | Also tagged , , , , , , , , , , , , , , , , | Leave a comment

FTC vs Actavis: Patent Settlements Become More Risky

Pharmaceutical companies can anticipate more costly, drawn-out patent litigation in the wake of the June 17 US Supreme Court decision, which creates great uncertainty about the grounds for negotiating settlements in patent cases. In ruling that “pay-for-delay” arrangements could violate the antitrust laws, and that the Federal Trade Commission (FTC) has the right to challenge […]
Posted in Guest Blog, Op-Ed, Regulatory | Also tagged , , , | Leave a comment
  • Categories

  • Meta